Compare ConocoPhillips (COP) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ConocoPhillips vs Inovio Pharmaceuticals Inc — how do they compare? ConocoPhillips trades at $134.19 (market cap $155.98B), while Inovio Pharmaceuticals Inc trades at $1.11 (market cap $119.42M). The key difference: ConocoPhillips is far larger — about 1306.1× Inovio Pharmaceuticals Inc's market cap, and ConocoPhillips pays a 2.59% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ConocoPhillips for 79 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| COP | INO | |
|---|---|---|
Market Cap | $155.98B | $119.42M |
Volume | 4,774,951 | 2,789,649 |
Sector | Energy | Health |
52-Week High | $141.22 | $2.65 |
52-Week Low | $85.66 | $0.66 |
Typical Hold Time | 79 Days | 43 Days |
Enterprise Value | $171.58B | $90.75M |
Dividend Yield | 2.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ConocoPhillips (COP) trades at $134.19, up 3.74% with strong technical momentum and bullish moving averages. The company shows solid fundamentals with Q2 2026 EPS beating expectations at $3.24 versus $2.90, supported by a 20-year LNG supply agreement with Venture Global announced October 1, 2026. Valuation metrics remain reasonable with P/E of 17.17 and EV/EBITDA of 6.17, while analyst consensus favors Buy ratings (75%) with a $154.75 price target.
Outlook remains positive given robust cash flow generation and strategic LNG expansion, though risks include oil price volatility and geopolitical exposure. The stock offers value with upside potential to analyst targets, but investors should monitor execution on international asset sales and energy market dynamics.
INO trades at $1.09, down 3.54% on the day, with a bearish technical signal driven by moving averages. The company reported a net loss of $84.95 million in 2025 on minimal revenue of $65,340, with negative profitability metrics, but has beaten EPS estimates in recent quarters. Key near-term catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107.
The investment case hinges on regulatory approval of INO-3107, with a consensus price target of $2.75 implying significant upside. However, extreme financial losses, high cash burn, and dependence on dilutive financing pose substantial risks. Analyst sentiment is cautiously optimistic but reflects high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ConocoPhillips
ConocoPhillips is a U.S.-based independent exploration and production firm. In 2021, it produced 1.0 million barrels per day of oil and natural gas liquids and 3.2 billion cubic feet per day of natural gas, primarily from Alaska and the Lower 48 in the United States and Norway in Europe and several countries in Asia-Pacific and the Middle East. Proven reserves at year-end 2021 were 6.1 billion barrels of oil equivalent.
Read more on COP →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
